parecoxib sodium is one of 98 small molecule programs targeting Total Knee Arthroplasty. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
797 competitors in Hepatocellular Carcinoma
parecoxib sodium
Ibrance
Viread
Sovaldi
Hepsera
Coreg
Apatinib
Doptelet
Miraclid
Vermox
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources